AJO

Audio Journal of Oncology in Advance - January 15th, 2007 - HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer

Ian Smith

IAN SMITH, Royal Marsden Hospital, London

REFERENCE: Lancet 369:29
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from the Herceptin Adjuvant (HERA) Study conducted among 3,000 women in Europe.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

Similar Interviews

  • Audio Journal of Oncology 13.8, December 2005
  • Reporting from: ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005 In this edition: Martine Piccart gave the Paris ECCO conference her

  • Audio Journal of Oncology in Advance - February 15th, 2007 - reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007">Audio Journal of Oncology in Advance - February 15th, 2007 - reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007
  • Rachel Johnson

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
  • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

    Post a comment

    Subscribe to Audio Medica Podcast